Sub-Navigation

• Calendar
• Live Events
• Investor Conferences
• Stockholders' Meeting
• Press Conferences
• Roadshows
• Other Presentations
• Archive

Bayer Links

• Bayer Global
• Sustainability
• Press
• Bayer in Social Media

Additionals

• General Conditions of Use
• Privacy Statement
• Imprint
• Technical Details

Klickpfad

• Home
• Events
• Archive
• Rivaroxaban Conference Call

Investor Conference Call
World Congress of Cardiology - Rivaroxaban Review

Tuesday, September 5, 2006

Start at approx. 6:00 p.m. CEST (4:00 p.m. GMT)

Dr. Gunnar Riemann
President of the Pharmaceuticals Division

Dr. Frank Misselwitz
Head Therapeutic Area Cardiovascular, Global Clinical Development

Here you find full details of the review of Rivaroxaban data presented at the World Congress of Cardiology 2006:

On-demand audio recording of the presentation and discussion

• Abstracts

WCC 2006 Abstracts on Rivaroxaban:

• Once-daily treatment with an oral, direct Factor Xa inhibitor - rivaroxaban (BAY 59-7939) - in patients with acute, symptomatic deep vein thrombosis. The EINSTEIN-DVT dose-finding study (Abstract P4568)
• Treatment of acute, symptomatic, proximal deep vein thrombosis with the oral, direct Factor Xa inhibitor rivaroxaban (BAY 59-7939) - the ODIXa-DVT dose-ranging study (Abstract P4569)
• Antithrombotic effects of rivaroxaban - an oral, direct Factor Xa inhibitor - in animal models of arterial and venous thrombosis: comparison with enoxaparin, an antithrombin-dependent anticoagulant (Abstract P4571)